Adagrasib

Major

Adagrasib Leniolisib Joenja Increased leniolisib exposure Details Adagrasib Lenvatinib Lenvima An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Levofloxacin Levaquin An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Levofloxacin Injection Levaquin An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Loperamide Diamode An increased risk of QT interval prolongation, an increased risk of other ventricular arrhythmias, cardiac arrest, an increased lo... Details Adagrasib Lovastatin Altocor® Increased CYP3A4 substrate exposure Details Adagrasib Lumateperone Caplyta Increased lumateperone exposure and an increased risk of lumateperone-related adverse reactions Details Adagrasib Lurasidone Latuda Increased CYP3A4 substrate exposure Details Adagrasib Lurbinectedin Injection Zepzelca Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details Adagrasib Maraviroc Selzentry Increased exposure to CYP3A/P-gp substrates Details Adagrasib Mefloquine Lariam® An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Meloxicam Alloxate Increased meloxicam exposure and reduced meloxicam metabolic clearance Details Adagrasib Meloxicam Injection Alloxate Increased meloxicam exposure and reduced meloxicam metabolic clearance Details Adagrasib Methylergonovine Methergine Increased methylergonovine exposure and an increased risk of vasospasm, cerebral ischemia and/or ischemia of extremities Details Adagrasib Metronidazole Flagyl An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Metronidazole Injection Flagyl An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Metronidazole Topical MetroCream® An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Metronidazole Vaginal MetroGel® Vaginal An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Mexiletine Mexitil® Increased exposure to CYP2D6 substrates and an increased risk of CYP2D6 substrates-relate adverse effects Details Adagrasib Midazolam Nasal Spray Nayzilam Increased CYP3A4 substrate exposure Details Adagrasib Midazolam Injection Nayzilam Increased CYP3A4 substrate exposure Details Adagrasib Midostaurin Rydapt Increased CYP3A4 substrate exposure Details Adagrasib Mitapivat Aqvesme Increased mitapivat exposure and an increased risk of mitapivat-related adverse reactions Details Adagrasib Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Adagrasib Moxifloxacin Avelox An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Moxifloxacin Injection Avelox An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Moxifloxacin Ophthalmic Moxeza® An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Nafarelin Nasal Spray Synarel An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Naloxegol Movantik Increased CYP3A4 substrate exposure Details Adagrasib Nifedipine Adalat® Increased NIFEdipine exposure and an increased risk of hypotension, bradycardia, or acute renal injury Details Adagrasib Nisoldipine Sular Increased CYP3A4 substrate exposure Details Adagrasib Octreotide Bynfezia An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Octreotide Injection Bynfezia An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Ofloxacin Floxin® An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Ofloxacin Ophthalmic Ocuflox An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Ofloxacin Otic Floxin® Otic An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details Adagrasib Olodaterol Oral Inhalation Striverdi An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Adagrasib Oxaliplatin Injection Eloxatin® An increased risk of QT interval prolongation, torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmias Details